Over the past two decades, Acinetobacter baumannii has emerged as a leading cause of nosocomial infections worldwide. Of particular concern are panresistant strains, leading the World Health Organization (WHO) to designate carbapenem-resistant A. baumannii as a priority 1 (critical) pathogen for research and development of new antibiotics. A key component in supporting this effort is accessibility to diverse and clinically relevant strains for testing. Here, we describe a panel of 100 diverse A. baumannii strains for use in this endeavor. Whole-genome sequencing was performed on 3,505 A. baumannii isolates housed at the Multidrug-Resistant Organism Repository and Surveillance Network. Isolates were cultured from clinical samples at health care facilities around the world between 2001 and 2017. Core-genome multilocus sequence typing and high-resolution single nucleotide polymorphism (SNP)-based phylogenetic analyses were used to select a final panel of 100 strains that captured the genetic diversity of the collection. Comprehensive antibiotic susceptibility testing was also performed on all 100 isolates using 14 clinically relevant antibiotics. The final 100-strain diversity panel contained representative strains from 70 different traditional Pasteur scheme multilocus sequence types, including major epidemic clones. This diversity was also reflected in antibiotic susceptibility and antimicrobial resistance (AMR) gene content, with phenotypes ranging from pansensitive to panresistant, and over 100 distinct AMR gene alleles identified from 32 gene families. This panel provides the most diverse and comprehensive set of A. baumannii strains for use in developing solutions for combating antibiotic resistance. The panel and all available metadata, including genome sequences, will be available to industry and academic institutions and federal and other laboratories free of charge.

中文翻译：

---

临床鲍曼不动杆菌研究和开发的不同小组。

在过去的二十年中，鲍曼不动杆菌已成为全球医院感染的主要原因。特别值得关注的是泛耐药菌株，导致世界卫生组织（WHO）将耐碳青霉烯的鲍曼不动杆菌指定为研究和开发新抗生素的优先1（关键）病原体。支持这项工作的关键因素是可访问多种与临床相关的菌株进行测试。在这里，我们描述了一组100种不同的鲍曼不动杆菌用于此工作。全基因组测序在3,505鲍曼不动杆菌上进行耐多药微生物库和监测网络中的分离株。在2001年至2017年期间，从临床样本中在世界各地的医疗机构中培养了分离株。使用核心基因组多基因座序列分型和基于高分辨率单核苷酸多态性（SNP）的系统发育分析来选择最终的100株菌株。集合的遗传多样性。还使用14种临床相关抗生素对所有100个分离株进行了全面的药敏试验。最终的100个菌株多样性小组包含来自70种不同的传统Pasteur方案多基因座序列类型（包括主要的流行克隆）的代表性菌株。这种多样性还反映在抗生素敏感性和抗菌素耐药性（AMR）基因含量上，其表型范围从全敏感到全抗，并从32个基因家族中鉴定出100多个不同的AMR基因等位基因。该面板提供了最多样化和最全面的鲍曼不动杆菌菌株用于开发对抗抗生素抗性的溶液。该小组和所有可用的元数据，包括基因组序列，将免费提供给行业和学术机构以及联邦和其他实验室。